Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Nambi

Showing results (151-160 of 160) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 160 results.
The Journal of Pharmacology and Experimental Therapeutics|June 1, 1996
Nonpeptide endothelin receptor antagonists. VII: Binding characteristics of [3H]SB 209670, a novel nonpeptide antagonist of endothelin receptorsP Nambi, M Pullen, H L Wu, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 1, 1994
Nonpeptide endothelin receptor antagonists. II. Pharmacological characterization of SB 209670E H Ohlstein, G R Beck, S A Douglas, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 1, 1996
Nonpeptide endothelin receptor antagonists. VI: Pharmacological characterization of SB 217242, a potent and highly bioavailable endothelin receptor antagonistE H Ohlstein, P Nambi, A Lago, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 16, 1994
SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonistE H Ohlstein, P Nambi, S A Douglas, et al.
Journal of Medicinal Chemistry|May 27, 1994
1,3-Diarylindan-2-carboxylic acids, potent and selective non-peptide endothelin receptor antagonistsJ D Elliott, M A Lago, R D Cousins, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 1, 1994
Nonpeptide endothelin receptor antagonists. I. Effects on binding and signal transduction on human endothelinA and endothelinB receptorsP Nambi, N Elshourbagy, H L Wu, et al.
Journal of Medicinal Chemistry|May 30, 1998
5-(5,6-Dichloro-2-indolyl)-2-methoxy-2,4-pentadienamides: novel and selective inhibitors of the vacuolar H+-ATPase of osteoclasts with bone antiresorptive activityS Gagliardi, G Nadler, E Consolandi, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 1, 1991
Vasopressin antidiuretic agonist and antagonist activity in dogs: structural and stereochemical relationship between bridge and carboxyl terminusC R Albrightson-Winslow, B Brickson, D P Brooks, et al.
Journal of Cardiovascular Pharmacology|November 15, 2000
Targeted disruption of the endothelin-B-receptor gene attenuates inflammatory nociception and cutaneous inflammation in miceD E Griswold, S A Douglas, L D Martin, et al.
Molecular Pharmacology|September 25, 1999
Endothelin B receptor modulates inflammatory pain and cutaneous inflammationD E Griswold, S A Douglas, L D Martin, et al.
Pageof 16

Showing results (151-160 of 160) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 160 results.
The Journal of Pharmacology and Experimental Therapeutics|June 1, 1996
Nonpeptide endothelin receptor antagonists. VII: Binding characteristics of [3H]SB 209670, a novel nonpeptide antagonist of endothelin receptorsP Nambi, M Pullen, H L Wu, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 1, 1994
Nonpeptide endothelin receptor antagonists. II. Pharmacological characterization of SB 209670E H Ohlstein, G R Beck, S A Douglas, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 1, 1996
Nonpeptide endothelin receptor antagonists. VI: Pharmacological characterization of SB 217242, a potent and highly bioavailable endothelin receptor antagonistE H Ohlstein, P Nambi, A Lago, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 16, 1994
SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonistE H Ohlstein, P Nambi, S A Douglas, et al.
Journal of Medicinal Chemistry|May 27, 1994
1,3-Diarylindan-2-carboxylic acids, potent and selective non-peptide endothelin receptor antagonistsJ D Elliott, M A Lago, R D Cousins, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 1, 1994
Nonpeptide endothelin receptor antagonists. I. Effects on binding and signal transduction on human endothelinA and endothelinB receptorsP Nambi, N Elshourbagy, H L Wu, et al.
Journal of Medicinal Chemistry|May 30, 1998
5-(5,6-Dichloro-2-indolyl)-2-methoxy-2,4-pentadienamides: novel and selective inhibitors of the vacuolar H+-ATPase of osteoclasts with bone antiresorptive activityS Gagliardi, G Nadler, E Consolandi, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 1, 1991
Vasopressin antidiuretic agonist and antagonist activity in dogs: structural and stereochemical relationship between bridge and carboxyl terminusC R Albrightson-Winslow, B Brickson, D P Brooks, et al.
Journal of Cardiovascular Pharmacology|November 15, 2000
Targeted disruption of the endothelin-B-receptor gene attenuates inflammatory nociception and cutaneous inflammation in miceD E Griswold, S A Douglas, L D Martin, et al.
Molecular Pharmacology|September 25, 1999
Endothelin B receptor modulates inflammatory pain and cutaneous inflammationD E Griswold, S A Douglas, L D Martin, et al.
Pageof 16